Cardiolipin-dependent reconstitution of respiratory supercomplexes from purified Saccharomyces cerevisiae complexes III and IV.

Here, we report for the first time in vitro reconstitution of the respiratory supercomplexes from individual complexes III and IV. Complexes III and IV were purified from Saccharomyces cerevisiae mitochondria. Complex III contained eight molecules of cardiolipin, and complex IV contained two molecules of cardiolipin, as determined by electrospray ionization-mass spectrometry. Complex IV also contained Rcf1p. No supercomplexes were formed upon mixing of the purified complexes, and low amounts of the supercomplex trimer III(2)IV(1) were formed after reconstitution into proteoliposomes containing only phosphatidylcholine and phosphatidylethanolamine. Further addition of cardiolipin to the proteoliposome reconstitution mixture resulted in distinct formation of both the III(2)IV(1) supercomplex trimer and III(2)IV(2) supercomplex tetramer. No other anionic phospholipid was as effective as cardiolipin in supporting tetramer formation. Phospholipase treatment of complex IV prevented trimer formation in the absence of cardiolipin. Both trimer and tetramer formations were restored by cardiolipin. Analysis of the reconstituted tetramer by single particle electron microscopy confirmed native organization of individual complexes within the supercomplex. In conclusion, although some trimer formation occurred dependent only on tightly bound cardiolipin, tetramer formation required additional cardiolipin. This is consistent with the high cardiolipin content in the native tetramer. The dependence on cardiolipin for supercomplex formation suggests that changes in cardiolipin levels resulting from changes in physiological conditions may control the equilibrium between individual respiratory complexes and supercomplexes in vivo.

Taming the induced folding of drug-targeted kinases.

Kinases have been exploited as anticancer drug targets but their conformational plasticity hinders the progress of structure-based design because the target might structurally adapt in unpredictable ways upon ligand binding. Thus, rational design of kinase inhibitors typically avoids targeting floppy regions. However, the level of amino acid conservation in such regions across homologous kinases is relatively low compared with structured regions, making them desirable binding sites to control specificity. Thus, we advocate for a much needed design concept to target unstructured regions. This concept applies to cases in which the floppy region cannot sustain structure owing to deficient packing. Thus, we propose the design of drugs that improve the packing quality of the kinase structure upon association, thereby steering induced folding. This concept is validated by dynamically examining structural adaptations promoted by imatinib redesigns intended to control drug specificity.

The intramolecular autoglucosylation of monomeric glycogenin.

The ability of monomeric glycogenin to autoglucosylate by an intramolecular mechanism of reaction is described using non-glucosylated and partially glucosylated recombinant glycogenin. We determined that monomer glycogenin exists in solution at concentration below 0.60-0.85 microM. The specific autoglucosylation rate of non-glucosylated and glucosylated monomeric glycogenin represented 50 and 70% of the specific rate of the corresponding dimeric glycogenin species. The incorporation of a unique sugar unit into the tyrosine hydroxyl group of non-glucosylated glycogenin, analyzed by autoxylosylation, occurred at a lower rate than the incorporation into the glucose hydroxyl group of the glucosylated enzyme. The intramonomer autoglucosylation mechanism here described for the first time, confers to a just synthesized glycogenin molecule the capacity to produce maltosaccharide primer for glycogen synthase, without the need to reach the concentration required for association into the more efficient autoglucosylating dimer. The monomeric and dimeric interconversion determining the different autoglucosylation rate, might serve as a modulation mechanism for the de novo biosynthesis of glycogen at the initial glucose polymerization step.

The size of the C-chain maltosaccharide of glycogen: evidence for the presence of only a single branch.

Glycogen is found in mammals and yeast bound to glycogenin forming proteoglycogen. The branched polysaccharide is joined to the protein through the C-chain, a maltosaccharide considered to be 13 glucose units long and double branched as the other branched glycogen B-chains. We described before the isolation of c-glycogenin, the debranched C-chain bound to glycogenin, from muscle proteoglycogen. In this work, the size of the C-chain is analyzed for the first time. The maltosaccharide moiety of c-glycogenin was auto[14C]glucosylated by a short incubation with UDP-[14C]glucose, and the labeled maltosaccharide was released by heating in 2 M NaOH containing 0.1 M NaBH4 and analyzed by high-performance thin layer chromatography (HPTLC). The results indicate that the C-chain is about half the size of the B-chains, not long enough to be double branched.